Janssen publicizes more Darzalex data
Genmab’s US partner Janssen has presented new data on the effect of the cancer drug Darzalex.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
On Friday, Genmab’s partner released more data from the phase III MAIA study with Darzalex (daratumumab). This data should not have a major effect on the Genmab share price.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Three global giants consider vaccine production in Denmark
For subscribers
